IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Daniel H. Teitelbaum

Serial No.: 10/798,470 Art Unit.: 1614

Filed: 03/11/2004 Examiner: P.G. Spivack
Entitled: Angiotensin Converting Enzyme Inhibitor Use For Treatment And

Prevention Of Gastrointestinal Disorders

SUPPLEMENTARY RESPONSE TO FINAL OFFICE ACTION MAILED JULY 31, 2007

EFS WEB FILED

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Examiner Spivack:

This supplementary amendment and response is responsive to the Final Office Action mailed July 31, 2007, and is being filed to meet the 37 CFR 1.333 Summary of Record of Interview Requirement.

It is not believed that any additional fees are necessary. However, if any fees are due, Applicants hereby authorize the Commissioner of the Patent and Trademark Office to charge Attorney Deposit Account No. **50-4302** any additional fees associated with this communication, and/or credit any overpayment. Please reference Attorney Docket No.: **UM-08764** when charging the Attorney Deposit Account.